Hispanic Heritage Month and Psychedelics
Celebrate National Hispanic Heritage Month by expressing gratitude for Hispanic and Latinx visionaries, researchers, community members, and others who have expanded awareness about psychedelics. Taking …
Participant Safety in Psychedelic Therapy
All stakeholders at the Multidisciplinary Association for Psychedelic Studies (MAPS) and MAPS Public Benefit Corporation (MAPS PBC) are committed to providing quality and comprehensive training and supervision …
Burning Man Volunteer Application Deadline Extended to June 24
The Zendo Project Burning Man volunteer application deadline has been extended to June 24, 2022! To learn more and apply, visit the Zendo Project website.
Now Recruiting for Investigator-Initiated Trial in Portland, Oregon
Recruitment of participants has begun at our investigator-initiated trial at Portland Psychotherapy in Portland, Oregon. Dr. Jason Luoma and a team of researchers are conducting this study to assess the …
MDMA Therapy Training Program Update: June 2022
Training staff and contractors pictured above, from left to right: Sara Gael Giron, Corey Westbury, Veena Muthusamy, Nicole Sylvestre, Chris Stauffer, Ryan Beauregard, Wesley Hale, Christine Penny, Bruce …
May 2022 Giving Report: Donors Give Over $675,000 to Psychedelic Research and Education
In May 2022, over 1,100 donors gave $675,834 in donations and pledges to MAPS. We are so grateful to these supporters who advance our shared vision of creating safe and legal opportunities for the beneficial …
An Open-Label Feasibility and Safety Study of MDMA-Assisted Group Therapy for the Treatment of Posttraumatic Stress Disorder in Veterans (MPG1) Response to Continued Clinical Hold
On May 23, 2022, MAPS submitted a complete response to the U.S. Food and Drug Administration (FDA) addressing the concerns outlined in the continued partial clinical hold for MAPS-sponsored Study MPG1. …
Phase 2 Study of Cannabis for Veterans with PTSD (MJP2) Regulatory Correspondences with FDA
Study MJP2 protocol was initially submitted on March 9, 2021. The study was put on hold by FDA on May 10, 2021 with additional comments for the hold provided on June 3, 2021. MAPS provided FDA with a response …
MAPS Appoints Jeff George and Dan Grossman to MAPS PBC Board of Directors
Experienced healthcare leaders bring decades of experience in global drug commercialization and patient access Appointment brings significant pharmaceutical leadership experience to the MAPS PBC board …
Christie’s Announces Cartography of the Mind: A Curated NFT Sale to Benefit MAPS
Christie’s is pleased to present Cartography of the Mind, a Curated NFT Sale to benefit the Multidisciplinary Association for Psychedelic Studies (MAPS) in collaboration with Ryan Zurrer, founder of …
Frontiers in Psychiatry: Ketamine for Bipolar Depression: Biochemical, Psychotherapeutic, and Psychedelic Approaches
Summary: Frontiers in Psychiatry discusses clinical considerations for route, dose, frequency, the importance of psychotherapy, and adverse events for ketamine for bipolar depression. Originally appearing …
April 2022 Giving Report: Donors Fund Psychedelic Research and Education With More Than $540,000 in Philanthropic Contributions
In April 2022, over 1,100 donors gave $540,085 in donations and pledges, advancing our shared vision of creating safe and legal opportunities for the beneficial uses of psychedelics. We are profoundly …